This hypothesis proposes that Alzheimer's disease pathology originates in the hippocampus and subsequently spreads to temporal, parietal, and prefrontal association cortices via transneuronal transmission of misfolded proteins along the projection pathways of affected neurons.
Type: Mechanistic Proposal
Confidence: Strong
Related Diseases: Alzheimer's disease, Primary age-related tauopathy
flowchart TD
subgraph Initiation_Sites
A["Entorhinal Cortex"] --> B["Hippocampus (CA1)"]
B --> C["Subiculum"]
end
subgraph Prion_Like_Propagation
D["Tau Misfolding"] --> E["Synaptic Release"]
E --> F["Axonal Transport"]
F --> G["Transsynaptic Transfer"]
G --> H["Recipient Neuron Uptake"]
H --> I["Tau Aggregation"]
end
subgraph Connectivity_Dependent_Spread
J["Hippocampal Output"] --> K["Posterior Cingulate"]
J --> L["Temporal Association Cortex"]
K --> M["Parietal Cortex"]
L --> M
M --> N["Prefrontal Cortex"]
end
subgraph Clinical_Progression
I --> O["Neuronal Dysfunction"]
N --> O
O --> P["Network Breakdown"]
P --> Q["Cognitive Decline"]
Q --> R["Memory Loss → → Global Cognition"]
end
subgraph Therapeutic_Targets
S["Anti-Tau Antibodies"]
T["Tau Aggregation Inhibitors"]
S --> E
T --> I
end
style A fill:#e3f2fd
style B fill:#e3f2fd
style D fill:#fff3e0
style I fill:#ffcdd2
style Q fill:#ff5252
style S fill:#c8e6c9
style T fill:#c8e6c9
Based on Braak model of neurofibrillary tau tangle progression (stages I-VI) and longitudinal MRI studies showing progression follows vulnerable fiber pathways rather than spatial proximity. This hypothesis posits a prion-like propagation mechanism where misfolded tau proteins transmit across synapses to connected neurons.
The transneuronal spread of tau pathology involves several interconnected mechanisms:
- Synaptic transmission: Tau proteins can be released at synapses and taken up by connected neurons
- Axonal transport: Misfolded tau propagates along microtubules within axons
- Exosome-mediated transfer: Extracellular vesicles facilitate interneuronal tau transmission
- Network vulnerability: Brain regions with high connectivity show earlier and more severe pathology
The classic Braak staging system describes the hierarchical spread of neurofibrillary tangles:
The prion-like spread of tau involves:
- Template-directed misfolding: Pathological tau serves as a template for normal tau conversion
- Oligomeric intermediates: Soluble tau oligomers are the transmissible species
- Synaptic vesicle release: Tau associates with synaptic vesicles for transsynaptic passage
- Microtubule disruption: Pathological tau destabilizes axonal transport
- Neuronal vulnerability: High-connectivity neurons are preferentially affected
Recent computational approaches using support vector machine (SVM) classifiers have validated the staging model, showing that spatial patterns of tau pathology can be accurately classified into Braak stages based on regional involvement patterns.
| Evidence Type |
Support Level |
Key Studies |
| Neuropathology |
Strong |
Braak & Braak 1991, extensive postmortem validation |
| Neuroimaging |
Strong |
PET tau tracers, longitudinal MRI |
| Animal Models |
Strong |
AAV-tau injection, seeding experiments |
| Human Tissue |
Strong |
Autopsy studies, biopsy validation |
| Computational |
Strong |
SVM classification, network analysis |
The evidence for hippocampal origin and transneuronal spread of AD pathology is robust:
- Consistent neuropathological staging across thousands of brains
- Validated by modern neuroimaging techniques
- Experimental proof of prion-like tau transmission in animal models
- PET imaging with tau tracers (Flortaucipir, others)
- Longitudinal MRI tracking regional atrophy
- CSF and blood biomarkers for tau species
- Postmortem neuropathological examination
Tau propagation represents a promising therapeutic target:
- Anti-tau antibodies in clinical trials
- Tau aggregation inhibitors in development
- Small molecules targeting tau secretion
- Braak & Braak (1991) - Neurofibrillary changes staging
- Raj et al. (2015) - SVM-based classification of tau pathology stages
- Cho et al. (2016) - Tau PET and Braak staging correlation
- Schubert et al. (2021) - Network-based tau spread modeling
- Distinguishing primary vs. secondary tau propagation
- Identifying the trigger of initial tau misfolding in entorhinal cortex
- Determining why some networks are preferentially vulnerable
hippocampus, entorhinal cortex, transentorhinal cortex, amygdala, temporal cortex, parietal cortex, prefrontal cortex, posterior cingulate
misfolded proteins, tau, amyloid-beta, phosphorylated tau, tau oligomers
tau pathology, prion-like propagation, synaptic transmission, brain connectivity network, Braak staging, neurofibrillary tangles
- Tau PET neuroimaging: Flortaucipir (AV-1451) and second-generation tracers
- Longitudinal MRI: Track atrophy patterns over time
- CSF biomarkers: p-tau181, p-tau217, p-tau231
- Postmortem neuropathology: Braak staging verification
- Blood-based tau biomarkers: p-tau217, p-tau181 assays
- Super-resolution microscopy: Tau oligomer visualization
- iPSC-derived neurons: Patient-specific propagation models
| Approach |
Target |
Status |
Clinical Trials |
| Anti-tau antibodies |
Extracellular tau |
Phase 2/3 |
NCT05338424, NCT04640008 |
| Tau aggregation inhibitors |
Intracellular tau oligomers |
Phase 1 |
NCT05539110 |
| Tau-targeted vaccines |
Passive/active immunization |
Phase 1/2 |
NCT05417147, NCT05239842 |
| Synaptic transmission blockers |
Tau release at synapses |
Preclinical |
- |
| Kinase inhibitors |
Tau phosphorylation reduction |
Phase 1 |
NCT04832138 |
| Microtubule stabilizers |
Normal tau function restoration |
Preclinical |
- |
| Antibody delivery methods |
Enhanced brain penetration |
Preclinical |
- |
¶ Clinical Trial Landscape
The therapeutic targeting of tau propagation has accelerated significantly:
- Anti-tau monoclonal antibodies: Multiple candidates in Phase 2/3 trials
- Small molecule inhibitors: Tau aggregation inhibitors entering clinical testing
- Active vaccination: Tau-based vaccines showing promise in early trials
- Gene therapy approaches: AAV-delivered anti-tau constructs in development
- Combination therapies: Amyloid removal + tau propagation blocking